false
0001442836
0001442836
2025-09-05
2025-09-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 5, 2025
MERSANA THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-38129 |
|
04-3562403 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
840
Memorial Drive
Cambridge,
Massachusetts |
|
02139 |
(Address of Principal Executive Offices)
|
|
(Zip
Code) |
Registrant’s telephone number, including
area code: (617) 498-0020
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common Stock, $0.0001 par value |
MRSN |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On September 5, 2025, Mersana Therapeutics, Inc. (the “Company”)
received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”), which
requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50.0 million. The Notice is only
a notification of deficiency, not of imminent delisting, and has no current effect on the listing of the Company’s common stock,
which continues to trade on The Nasdaq Global Select Market under the symbol “MRSN.”
In accordance with the MVLS Rule, the Company has a period of 180 calendar
days, or until March 4, 2026 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance, the Company’s
MVLS must close at $50.0 million or more for a minimum of ten consecutive business days prior to the Compliance Date. In the event the
Company does not regain compliance with the MVLS Rule prior to the Compliance Date, Nasdaq will notify the Company that its securities
are subject to delisting. At that time, the Company will have the opportunity to appeal the delisting determination to a Nasdaq hearings
panel. The Company intends to monitor its MVLS and consider its available options to regain compliance with the MVLS Rule. However, there
can be no assurance that the Company will be able to regain compliance with the MVLS Rule or maintain compliance with other Nasdaq listing
rules.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
MERSANA THERAPEUTICS, INC. |
| |
|
|
| Date: September 5, 2025 |
By: |
/s/ Brian DeSchuytner |
| |
|
Brian DeSchuytner |
| |
|
Senior Vice President, Chief Operating Officer and Chief Financial Officer |
